secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001493152-22-021961
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q2 net loss $4M, secures $5M insider debt, adds ADHD expert to board
------------------------------------------------------------------------------

- Q2 2022 net loss $4.0M (vs $1.4M Q2 2021); six-month net loss $9.0M (vs $2.8M).
- Cash $8.2M at June 30, 2022, down from $16.5M Dec 2021; expects to fund through Q1 2023.
- Secured $5M unsecured debt from Werth Family Investment at 15% interest, due 2025; quarterly call option from Apr 2023.
- Appointed Scott Applebaum to board; brings 10+ years ADHD expertise from Shire (Adderall XR, Vyvanse).
- CTx-1301 Phase 3 pediatric trial dosing H2 2022, results H2 2023; company needs ~$16.5M additional capital for NDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315222021961/0001493152-22-021961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315222021961/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-021961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer